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AbstrACt 
Objectives A short-term and long-term cost-effectiveness 
analysis (CEA) of two pedometer-based walking 
interventions compared with usual care.
Design (A) Short-term CEA: parallel three-arm cluster 
randomised trial randomised by household. (B) Long-term 
CEA: Markov decision model.
setting Seven primary care practices in South London, 
UK.
Participants (A) Short-term CEA: 1023 people (922 
households) aged 45–75 years without physical activity 
(PA) contraindications. (b) Long-term CEA: a cohort of 
100 000 people aged 59–88 years.
Interventions Pedometers, 12-week walking 
programmes and PA diaries delivered by post or through 
three PA consultations with practice nurses.
Primary and secondary outcome 
measures Accelerometer-measured change (baseline to 
12 months) in average daily step count and time in 10 min 
bouts of moderate to vigorous PA (MVPA), and EQ-5D-5L 
quality-adjusted life-years (QALY).
Methods Resource use costs (£2013/2014) from 
a National Health Service perspective, presented as 
incremental cost-effectiveness ratios for each outcome 
over a 1-year and lifetime horizon, with cost-effectiveness 
acceptability curves and willingness to pay per QALY. 
Deterministic and probabilistic sensitivity analyses 
evaluate uncertainty.
results (A) Short-term CEA: At 12 months, incremental 
cost was £3.61 (£109)/min in ≥10 min MVPA bouts for 
nurse support compared with control (postal group). At 
£20 000/QALY, the postal group had a 50% chance of 
being cost saving compared with control. (B) Long-term 
CEA: The postal group had more QALYs (+759 QALYs, 
95% CI 400 to 1247) and lower costs (−£11 million, 95% CI 
−12 to −10) than control and nurse groups, resulting in 
an incremental net monetary benefit of £26 million per 
100 000 population. Results were sensitive to reporting 
serious adverse events, excluding health service use, and 
including all participant costs.
Conclusions Postal delivery of a pedometer intervention 
in primary care is cost-effective long term and has a 
50% chance of being cost-effective, through resource 
savings, within 1 year. Further research should ascertain 
maintenance of the higher levels of PA, and its impact on 
quality of life and health service use.
trial registration number ISRCTN98538934; Pre-results.
IntrODuCtIOn
Increasing physical activity (PA) is a 
widely stated policy aim from local to inter-
national level.1 2 Walking is a safe and, poten-
tially cheap, activity that has the potential 
to reduce cardiovascular disease (CVD), 
strengths and limitations of this study
 ► This study provides the first primary data on the 
short-term costs associated with delivering pe-
dometers to a large (n=1023), population-based 
sample from primary care alongside a high-quality 
randomised controlled trial that achieved a 93% fol-
low-up rate at 12 months.
 ► Results from the trial are fed into a peer-reviewed, 
policy-relevant Markov model to estimate long-term 
cost-effectiveness as trials of public health interven-
tions are unable to reflect the balance of costs and 
effects when benefits occur in the long term.
 ► Results are tested in a number of sensitivity analy-
ses to assess the impact of changing perspective, 
missing data, changed assumptions about mainte-
nance of physical activity (PA) and of taking more 
conservative views of outcomes and cost impact.
 ► The main limitation of the economic analysis is the 
lack of information about the likelihood of maintain-
ing PA beyond 3 years into the long term and the 
exclusion of long-term impacts on other conditions, 
for example, cancers.  on
 5 N
ovem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021978 on 17 October 2018. Downloaded from 
2 Anokye N, et al. BMJ Open 2018;8:e021978. doi:10.1136/bmjopen-2018-021978
Open access 
diabetes, cancer and poor mental health.3 It is therefore 
important to establish which approaches are effective at: 
encouraging inactive people to do at least some walking; 
increasing the number of people walking briskly for at 
least 150 min/week (ie, achieving moderate to vigorous 
PA (MVPA) guidelines2); and/or maintaining increases 
in walking over time. This would also provide the basis for 
estimating cost-effectiveness and supporting recommen-
dations for policy and practice.
Until recently, the best evidence of pedometer-based 
walking programmes was from systematic reviews that 
relied on small, short-term studies where the indepen-
dence of pedometer effects from other support provided 
was unclear.4 These had shown that walking interven-
tions can achieve increases of ~2000–2500 steps/day 
at 3 months, but often relied on volunteer samples or 
high-risk groups and did not assess time in MVPA, as 
defined in PA guidelines, as an outcome. New evidence 
from a large randomised trial clustered by household 
(Pedometer and Consultation Evaluation-UP, PACE-UP) 
compared delivery of pedometers by post or through 
primary care nurse-supported PA consultations. The trial 
was undertaken with 1023 inactive primary care patients 
aged 45–75 years from seven practices in South London. 
Results showed that step counts increased by around 10% 
and time in MVPA in 10 min bouts by around a third, 
with both the nurse and postal delivery arms achieving 
similar 12-month outcomes.4 This is important because 
primary care can be a key to reaching directly into the 
community and offering continuity of care for increasing 
PA. It is shown that this type of intervention is suitable for 
older adults, where exercise referral schemes have been 
disappointing.4 Compared with national averages (from 
Health Survey for England 2012 data set) for the same 
age range of the PACE-UP trial, the trial sample was more 
overweight/obese (66% vs 61%), more likely to have/
have had a higher managerial, administrative, profes-
sional occupation (59% vs 36%) and less likely to be white 
(80% vs 93%).
Other than a small, highly selected study which limited 
outcomes to steps achieved among 79 people from 
one family physician practice in Glasgow,5 there is no 
primary evidence of the cost-effectiveness of pedometer 
programmes in the UK. Elsewhere, in Australia, New 
Zealand and the Netherlands, economic models from 
community-based adults with low PA levels compare 
pedometer prescriptions and pedometer-based telephone 
coaching with usual practice.6–8 These indicate pedome-
ter-based interventions may be cost-effective in the long 
term, but estimates vary widely and generalisability is not 
considered.9
The analytic horizon of cost-effectiveness analyses 
should extend far enough into the future to capture 
all benefits and harms, although in practice this can be 
limited by the amount and quality of data.10 The National 
Institute for Health and Care Excellence’s (NICE) public 
health guidance11 also recommends providing results 
that reflect the short term (1–3 years). This is reinforced 
in NICE’s return on investment models,12 which argue 
that shorter term decision-making is of key interest to 
some decision-makers and which have been used by 
commissioners.
This paper estimates the short-term (1 year) and long-
term (lifetime) cost-effectiveness of pedometers deliv-
ered by post or through practice nurse consultation for 
1023 inactive adults aged 45–75 years. The short-term 
evaluation arises from a within-trial analysis of individual 
resource use and costs of interventions provided in the 
PACE-UP trial.4 The cost and effectiveness results from 
the trial are used to populate a long-term model13 for life-
time cost-effectiveness.
MethODs
short-term cost-effectiveness
The short-term within-trial cost-effectiveness analysis was 
conducted alongside the PACE-UP trial4 14 that evaluated 
two intervention groups against control (no intervention 
group). The two intervention groups received pedome-
ters (SW-200 Yamax Digi-Walker) (one by post), patient 
handbook; PA diary (including individual 12-week walking 
plan), with the nurse group also offered three individu-
ally tailored practice nurse PA (10–20 min) consultations 
(nurse support group only) at approximately weeks 1, 5 
and 9.4 The control group followed usual practice and 
were not provided with any feedback on their PA levels or 
materials promoting PA during the trial.4 These interven-
tions could therefore evaluate the incremental effect of 
adding nurse support to pedometers.
The costs for the two intervention arms include set-up 
costs, staff training and intervention delivery (including: 
pedometers and clips, batteries, handbooks, diaries, 
postage, nurse time, time making appointments). 
Measures of each resource use were taken from admin-
istrative/trial management records, computer-based 
diaries and interviews with the trial manager and prin-
cipal investigator. To account for potential changes in 
falls, change in use of health services following differ-
ential contact of health services by participants or unin-
tended resource consequences, general health service 
use (eg, general (family) physician visits, hospital admis-
sions, accident and emergency attendances, referrals) 
was collected at participant level, through a one-time 
download of physician records at the end of the trial, and 
linked to procedure codes using PI judgement (blind to 
treatment group) to facilitate costing across elective and 
non-elective admissions. Information on costs borne by 
patients (eg, time use, out-of-pocket expenses associated 
with walking groups, plus any related travel costs) was 
collected by questionnaire at 3 and 12 months. Resources 
were valued using national tariffs where possible15 16 to 
increase generalisability; where not available tariffs from 
St Georges Hospital, London, were used. All costs are 
expressed in £2013–2014 sterling, inflated to this base 
year where appropriate using the Hospital & Commu-
nity Health Service inflation index. As the trial lasted for 
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1 year, a discount rate was not applied (see online supple-
mentary tables S1–S5). PA was measured objectively 
by accelerometry (GT3X+, ActiGraph) and data were 
reduced using ActiLife software (V.6.6.0). The summary 
variables used were as follows: step counts; and time spent 
in MVPA in ≥10 min bouts (≥1952 counts/min, equiva-
lent to ≥3 metabolic equivalents).17
Outcomes were: (A) changes in daily steps and weekly 
minutes of MVPA in bouts of ≥10 min, and (B) changes in 
quality-adjusted life-years (QALY), based on participant 
completion of the EQ-5D-5L questionnaires at baseline, 
and 3 and 12 months. Utility weights were assigned using 
the ‘crosswalk’ function18 linked to the standard UK-based 
weights,19 with QALYs based on the area under the curve.
Standard practice for accounting for missing data was 
followed.20 21 Patterns of missing data were investigated, 
with multiple imputation by chained equations fitted 
to replace item non-response. Missing EQ-5D data were 
replaced using an index rather than domain imputation 
as recommended.22 Mean imputation was used where 
missing data were ≤5%.23 Imputation models were fitted 
to match the model used for main analysis while including 
the predictors of missingness as appropriate. Second, the 
dependent variables were included in imputation models 
to ensure that the imputed values have similar relation-
ships to the dependent variable as the observed values.24
Results are reported, from a National Health Service 
(NHS) perspective, as incremental cost-effectiveness 
ratios (ICER) for cost per change in daily steps and cost 
per QALY for a 1-year time period, adjusted for baseline 
differences. A generalised linear model was fitted sepa-
rately for costs and QALYs with clustered SEs. To provide 
more precise estimates of uncertainty, the ‘margins 
method’ was used to generate sample means by trial arm 
for costs and QALYs.24 Cost models were fitted using the 
Poisson distribution and QALY models using the bino-
mial 1 family, equivalent to beta regression.25 The choice 
of distributional family for the models was based on the 
modified Park test and comparison of observed and 
predicted values. Covariates included baseline level (for 
the QALY-based models),26 practice and variables found 
to be correlates of PA-related outcomes,27 that is, demog-
raphy (age, gender, ethnicity, marital status, education, 
employment, socioeconomic status, cohabitation), 
health (number of disease conditions) and other life-
style behaviours (smoking and alcohol intake). Reduced 
models were generated using Wald tests to examine the 
joint significance of variables found not to be significant 
(at 5%) in the base model.
Deterministic sensitivity analyses assessed: (A) inclu-
sion of all randomised patients (rather than only those 
who provided accelerometry data); (B) exclusion of costs 
of general health service use beyond immediate inter-
vention; (C) exclusion of missing data; (D) methods of 
accounting for adverse events; (E) perspective of anal-
ysis (ie, including all and parts of participant costs); (F) 
varying the length of life of a pedometer; (G) the combi-
nation of excluding all health service use costs; and (H) 
including participant costs related to participation in 
PA and the interventions (minus health service use cost 
borne by participants, to ensure consistency in perspec-
tive). To reflect stochastic uncertainty surrounding mean 
incremental cost-effectiveness, cost-effectiveness planes 
and cost-effectiveness acceptability curves (CEAC) were 
constructed using 2000 non-parametric bootstrap samples 
from the base case estimates.
Long-term cost-effectiveness
A Markov model used to support NICE public health guid-
ance28 and return on investment modelling12 was adapted 
to examine the long-term (lifetime) cost-effectiveness. 
From an NHS perspective, costs (2013/2014 prices) and 
health outcomes from reduced disease, expressed as 
QALYs, were discounted at the rate of 3.5% per annum. 
Results are reported as ICER, CEAC and incremental net 
benefit statistics.
In the original model,13 a cohort of 100 000 people 
aged 33 years were followed in annual cycles over their 
lifetime. At the end of the first year of the model, the 
cohort is either ‘active’ (doing 150 min of MVPA in 10 
min bouts per week) or ‘inactive’ and they could have 
one of three events (non-fatal coronary heart disease 
(CHD), non-fatal stroke, type 2 diabetes (T2D)), remain 
event free (ie, without CHD, stroke or diabetes) or die 
either from CVD or non-CVD causes, each of which had 
assigned annual treatment costs (split by initial event and 
follow-up). After the first year, people would revert to 
PA patterns observed in long-term cohort studies (up to 
10-year cycle in the model) on the relationship between 
PA and disease conditions.13 The key driver of the long-
term model is the protective effects of PA, which is a func-
tion of PA patterns after the first year of the intervention. 
In the base case analysis, PA behaviour was based on PA 
patterns observed in long-term cohort studies29–31 on the 
relationship between PA and disease conditions. The 
cohort studies used followed up the same people (who 
were either active or inactive at baseline) for 10 years, 
during which some of the inactive people might have 
become active or vice versa. Thus, the impact of changing 
habits is incorporated in the cohort relative risk (RR) 
estimates from these epidemiological studies. However, 
assuming that these estimates would persist after the 
follow-up periods might be impractical. It was therefore 
assumed, conservatively, that these RR estimates held for 
an initial 10-year period (ie, the period PA patterns were 
observed in the epidemiological studies), after which 
no protective benefit would persist. Hence, the RRs for 
developing CHD, stroke and T2D in the first 10 years of 
the model were based on the estimates from the epide-
miological studies but from year 11 onwards they were 
assumed to be equal to 1 (no effect). This assumption was 
tested for sensitivity analyses.
Active individuals had lower risks of developing CHD, 
stroke and T2D. People who become active in the first 
year (irrespective of trial arm) also accrue short-term 
psychological benefits, a one-off utility gain associated 
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with achieving the recommended level of PA13 (see online 
supplementary figure S1).
The model was adapted using data from the PACE-UP 
trial in the following ways: (A) a cohort of 100 000 people 
aged 59 years followed, in annual cycles, to 88 years, 
reflecting the average age of all trial participants at base-
line and the average life expectancy for people aged 59 
years in the UK32 and exposed, at this age, to interven-
tions (either nurse or postal) in an unexposed popula-
tion, that is, control group/usual care:
a. Age-specific estimates were revised to reflect the 
change in the cohort age.
b. Within-trial cost of interventions was used, with a sec-
ond year of annuitised values included appropriate-
ly—postal (£5.03/person) and nurse group (£4.14/
person).
c. Effectiveness was reflected as the RR of achiev-
ing ≥150 MVPA min/week in ≥10 min bouts.
d. Short-term psychological benefits of PA (one-off utility 
gain) estimated using beta regression fitted for EQ-5D 
scores at 12 months for active people controlling for 
EQ-5D scores at baseline, demographics, practice, dis-
ability and trial arm using.
All other parameters remained the same as the orig-
inal model, based on literature reviews or evidence from 
national/international science-based guidance on PA 
and health. Parameter estimates are provided in online 
supplementary table S6.
Deterministic sensitivity analysis explored four conser-
vative scenarios: (1) Assuming the protective effects of PA 
exist only for 1 year, as the trial MVPA data were assessed 
at 12 months. (2) Assuming the protective effects of PA 
exist for 3 years. Recent evidence33 relating to 3-year 
follow-up of participants of the interventions showed 
persistent effect at 3 years. (3) Exclusion of all health 
service use cost consequences during trial period (model 
year 1) and assumed no psychological benefits in the first 
year of being physically active. This was considered due 
to the uncertainty around short-term changes to health 
service use and because previous studies found the exclu-
sion of short-term QALY gain associated with being phys-
ically active to affect conclusions.13 (4) Scenario 3 plus all 
patient costs related to participation in PA and the inter-
ventions (details of the participant costs are provided in 
online supplementary table S4). Probabilistic sensitivity 
analysis was based on 10 000 Monte Carlo simulations and 
included all parameters except baseline mortality, as the 
mortality census data have little uncertainty.
Patient and public involvement
Patient and public involvement across the study is 
described in our publication of the main results4 and 
is reproduced below under the terms of the Creative 
Commons Attribution Licence (CC BY 4.0).
Pilot work with older primary care patients from three 
general practices was carried out ahead of seeking trial 
funding, with focus groups at each practice discussing 
ideas for a pedometer-based PA intervention. Patients 
were enthusiastic about the study and felt that the postal 
approach to recruitment and the interventions offered 
would be acceptable. They had input into aspects of the 
study design; for example, they encouraged us to offer the 
usual care arm a pedometer at the end of the follow-up 
period and they encouraged us to recruit couples as 
well as individuals, and to allow couples to attend nurse 
appointments together.
A patient advisor was a Trial Steering Committee 
member and was involved in discussions about recruit-
ment and study conduct, as well as advising about patient 
materials, dissemination of results to participants and 
safety reporting mechanisms.
All participants were provided with timely feedback of 
their individual trial results after completion of 12-month 
follow-up, including their PA and body size measures over 
the trial duration. Summaries of results for the whole 
trial were disseminated to all trial participants as A4 feed-
back sheets after completion of baseline assessments and 
after analysis of the main results. A trial website (http://
www. paceup. sgul. ac. uk/) has been created, and details 
have been circulated to participants. This also provides 
a summary of the trial results and details about further 
trial follow-up. All publications relating to the trial are 
provided on the website.
The burden of the intervention was assessed by all 
participants in the nurse group with a questionnaire as 
part of the process evaluation34 and by samples of both 
intervention groups as part of the qualitative evaluation.35
resuLts
short-term cost-effectiveness
Table 1 summarises data on costs, EQ-5D-5L utility scores 
and QALYs by trial arm. At 3 months, average cost per 
participant was highest in the nurse group (£249) followed 
by the postal (£122) and control group (£107). In terms 
of the components of total costs, the cost of nurse-sup-
ported pedometer delivery was seven times greater (£50) 
than the postal group (£7), and set-up costs were double. 
Comparing the trial arms based on cost of health service 
use shows that the control group costs £35 more per 
participant than the postal group and £12 more than the 
nurse group. Results are similar at 12 months, except for 
the control arm, which has a higher overall average cost 
than the postal arm.
Table 2 shows that, at 3 months, mean incremental costs 
were significantly higher for the nurse group compared 
with the postal (+£120, 95% CI £95 to £146) and control 
groups (+£135, 95% CI £99 to £171) but not statistically 
significantly higher for the postal compared with control 
group. While increases in both daily steps and weekly 
minutes of MVPA in ≥10 min bouts for both interventions 
compared with control, and for the nurse group compared 
with postal (nurse: +481 steps (95% CI 153 to 809), +18 
min MVPA (95% CI 1 to 35)) were statistically significant, 
the small mean decrease in QALYs is not statistically signif-
icant for any comparison. The cost per additional minute 
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of MVPA was 35p for postal group and £2.21 for the nurse 
group and therefore the (slightly) fewer QALYs for both 
interventions compared with control contributed to the 
dominance of each intervention by the control group 
(ie, the control group cost less and had more QALYs). 
To move from a postal to nurse-delivered pedometer 
would cost 25p per additional step and £6.67 per addi-
tional MVPA-min. However, in terms of cost-effectiveness, 
the nurse group costs more and produces less QALYs on 
average than the postal group at 3 months.
Results differ at 12 months. Compared with the control 
group, the postal arm cost less on average (−£91) and the 
nurse group more (+£126) but neither are statistically 
significant. The increase in cost of moving from a postal 
to nurse delivery is also statistically significantly higher 
(+£217, 95% CI £81 to £354). While both interventions 
are associated with a statistically significant increase 
in steps and weekly minutes of MVPA, the difference 
between intervention groups is not statistically significant 
at 12 months. The small decrements in QALYs at each 
incremental comparison are not statistically different. 
The postal group took more steps (+642) and cost less 
on average (−£91) compared with control and dominates 
control in terms of PA outcomes. The nurse group cost 
19p per additional step and £3.61 per additional minute 
of MVPA compared with control, with this rising to £6 and 
£109, respectively, when compared with the postal group. 
In terms of QALYs, the nurse group is still dominated (ie, 
cost more and had worse outcomes) by the control and 
postal groups. However, on average, each QALY lost in 
the postal group compared with control is associated with 
a saving of £21 162, which could therefore be considered 
cost-effective.
The probabilistic sensitivity analyses broadly confirm 
the findings of the base case; the postal group is most 
often associated with lower QALYs along with cost 
savings and the nurse group tends to have both lower 
QALYs and higher costs compared with control and 
postal group (online supplementary tables S2–S4 and 
supplemmentary figures S3 and S4). Figure 1 shows 
that at £20 000 per QALY gained/lost, the postal group 
has a 50% chance of being cost-effective compared 
with control (usual care). This falls to 42% at £30 000/
QALY, which reflects the postal group having most 
observations in the lower left-hand quadrant (as seen 
in online supplementary figure S2). Figure 1 also shows 
that, at a willingness to pay/lose a QALY of £20 000, the 
nurse group has a 5.5% chance of being cost-effective 
compared with control.
The deterministic sensitivity analyses (online supple-
mentary table S7) mostly produced results consistent with 
the base case findings. However, in four circumstances, 
usual care would dominate both the postal and nurse 
groups at 12 months: (1) using health service use based 
on self-reported serious adverse effects; (2) excluding all 
health service costs; (3) changing perspective (including 
Table 1 Average costs and QALYs per participant, by trial arm (£2013/2014 sterling, all randomised participants who provided 
required accelerometry data*, missing data imputed)
Cost and quality of life (EQ-5D-5L)
Control Postal† Nurse†
Mean (SD)
0–3 months n=318 n=317 n=319
Total cost £107 (254) £122 (107) £249 (215)
  Set-up £0 (0) £45 (0) £105 (0)
  Delivery of intervention £0 (0) £7 (0) £50 (18)
  Health service use £107 (254) £71 (107) £95 (214)
EQ-5D scores at baseline 0.839 (0.14) 0.853 (0.12) 0.851 (0.12)
EQ-5D scores at 3 months 0.844 (0.14) 0.848 (0.14) 0.841 (0.14)
QALYs 0–3 months 0.194 (0.03) 0.196 (0.03) 0.195 (0.03)
0–12 months n=323 n=312 n=321
  Total cost £461 (916) £375 (611) £603 (987)
  Set-up £0 (0) £45 (0) £105 (0)
  Delivery of intervention £0 (0) £10 (0) £52 (18)
  Health service use £461 (916) £320 (611) £447 (987)
EQ-5D scores at baseline 0.837 (0.14) 0.850 (0.12) 0.849 (0.13)
EQ-5D scores at 3 months 0.840 (0.14) 0.847 (0.13) 0.837 (0.14)
EQ 5D scores at 12 months 0.833 (0.15) 0.836 (0.13) 0.831 (0.14)
QALYs 0–12 months 0.837 (0.13) 0.843 (0.11) 0.836 (0.13)
*The number of people who provided accelerometry data differed across time points within arms. 
†For incremental analyses, the comparisons are postal versus control and nurse versus control.
QALY, quality-adjusted life-year.
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all participant costs); and (4) the worst case ‘combined 
scenario’ sensitivity analyses.
Long-term cost-effectiveness
Table 3 shows that, over the remaining lifetime from age 
59, the nurse group would be costlier (£11 million, 95% CI 
£10 million to £12 million) but have more QALYs (671, 
95% CI 346 to 1071) per 100 000 population than the 
control group and therefore provide each additional QALY 
at a cost of £16 368. However, the postal group would have 
lower lifetime costs than the control arm (−£11 million per 
100 000 population, 95% CI −£12 million to −£10 million) 
and more QALYs (759, 95% CI 400 to 1247); it is therefore 
the dominant option, with an incremental net benefit of 
£26 million per 100 000 population (95% CI £18 million to 
£36 million). These results are confirmed by the incre-
mental net benefit, which shows the £2 million per 100 000 
for nurse group compared with control is not significantly 
different and compared with the post group is significantly 
negative (−£24 million, 95% CI −£27 to −£21).
The stochastic uncertainty associated with the mean 
ICER (figure 2) indicates the above findings are robust. 
There is a 100% likelihood, at a willingness to pay 
£20 000/QALY, that the postal group is cost-effective 
compared with the control and nurse groups. This is 
consistent with the estimates of net monetary benefit in 
table 3. At £20 000/QALY, there is a 70% likelihood that 
the nurse group would be cost-effective compared with 
control (figure 2).
The results for the sensitivity analyses were:
a. Scenario 1: (1) postal versus control: postal remained 
dominant, less expensive (−£9 million) with more 
QALY gains (+211 QALYs); (2) nurse versus control: 
the ICER further increased from £16 000 to £69 000 
(+£12.8 million, +186 QALYs); (3) nurse versus postal: 
the nurse group remained dominated by postal group 
(+£21.6 million, −32 QALYs).
Figure 1 Cost-effectiveness acceptability curve showing 
the probability of short-term (at 1 year) cost-effectiveness for 
postal and nurse groups (vs control) at different willingness to 
pay per quality-adjusted life-year (QALY) thresholds.
Table 3 Costs, effects and cost-effectiveness over a lifetime from age 59 (cohort of 100 000 people)
Control Postal* Nurse* Nurse versus postal
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Lifetime total cost 
(£ million)†
340 (307 to 371) 329 (296 to 361) 351 (318 to 384) – 
Lifetime incremental 
cost (£ million)
– −11 (−12 to 10) 11 (10 to 12) 22 (21 to 23)
Lifetime total QALYs 
(million)
1.0709 (0.879 to 1.273) 1.0717 (0.889 to 1.274) 1.0716 (0.880 to 1.273) – 
Lifetime incremental 
QALYs
– 759 (400 to 1247) 671 (346 to 1071) −108 (−223 to −10)
Lifetime ICER for 
QALYs (£)
Postal dominates control 16 368 Postal dominates nurse
Lifetime incremental 
net monetary benefit 
(£ million, @£20 000 
per QALY)
– 26 (18 to 36) 2 (−5 to 11) −24 (−27 to −21)
*For incremental analyses, the comparisons are postal versus control and nurse versus control.
†£46.7 million, £37.6 million and £59.3 million of the total costs for control, postal and nurse groups, respectively, were estimated using 
Pedometer and Consultation Evaluation-UP (PACE-UP) trial results.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year. 
Figure 2 Cost-effectiveness acceptability curve showing 
the probability of lifetime cost-effectiveness for postal and 
nurse groups (vs control) at different willingness to pay per 
quality-adjusted life-year (QALY) threshold levels.
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b. Scenario 2: (1) postal versus control: postal was still 
dominant, less expensive (−£9.2 million) with more 
QALY gains (+327 QALYs); (2) nurse versus con-
trol: the ICER increased from £16 000 to £43 000 
(+£12.4 million, +289 QALYs); (3) nurse versus postal: 
the nurse group remained dominated by postal group 
(+£21.7 million, −48 QALYs).
c. Scenario 3: (1) postal versus control: postal moved 
from a dominant position to a more expensive option 
(+£4 million) with more QALY gains (+609 QALYs), 
and an ICER of £6100; (2) nurse versus control: the 
ICER increased from £16 000 to £26 000 (+£14 mil-
lion, +538 QALYs); (3) nurse versus postal: the nurse 
group remained dominated by postal group (+£10 mil-
lion, −87 QALYs).
d. Scenario 4: (1) postal versus control: postal moved from 
a dominant position to more expensive (+£16 million) 
and more QALY gains (+609 QALYs) with an ICER of 
£26 600; (2) nurse versus control: the ICER increased 
from £16 000 to £25 400 (+£13.7 million, +538 QALYs); 
(3) nurse versus postal: nurse moved from dominated 
position (where costs are higher and QALYs lower) to 
a cost-effective position (where both costs and QALYs 
are lower) (−£2 million, −87 QALYs).
DIsCussIOn
The lifetime cost-effectiveness of posting a pedometer 
with written instructions to a cohort of 100 000 insuffi-
ciently active people aged 59 years (who have indicated 
an interest in research or participation in walking) would 
cost less (−£11 million, 95% CI −12 to −10) and provide 
more QALYs (759 QALYs, 95% CI 400 to 1247) than usual 
care. Most cost savings and quality of life benefits derive 
from reductions in stroke, CHD and T2D. This finding 
was robust (incremental net benefit of £26 million, 
95% CI £18 million to £36 million) and sensitivity analyses 
showed that even excluding short-term cost savings would 
not change the conclusion that the postal group would be 
extremely cost-effective in the long term (ICER: £6100/
QALY). Sending a pedometer by post with instructions 
from a primary care provider to inactive people aged 
45–75 also has a 50% chance of being cost-effective within 
a year, as a 1 QALY loss was associated with saving over 
£21 000. The nurse group had higher costs and lower 
QALYs than both control and postal groups at 1 year. 
While sensitivity analyses did not change conclusions in 
most cases, in three cases (using self-reported serious 
adverse events, excluding health service use, including all 
participant costs) it did, indicating that the control group 
would dominate (ie, have lower costs and more QALYs) 
than both the postal and nurse groups.
A key strength of this study is the base of individualised 
cost and effectiveness data on a large, population-based, 
cluster randomised controlled trial with excellent 
follow-up data to 1 year (93.4%, Harris et al),4 designed 
to produce generalisable results, for cost per QALY esti-
mates at 1 year and as inputs to a long-term model of 
cost-effectiveness. It is also the only study to have included 
provider and user perspectives, extended commonly used 
techniques to account for clustering and used conserva-
tive assumptions for both short-term and long-term sensi-
tivity analyses.
One weakness of the within-trial cost-effectiveness study 
concerns the use of PI judgement to determine costs of 
admissions, and therefore alternative assumptions were 
explored in sensitivity analyses. Patient-reported cost data 
were collected for months 1–3 and 9–12, with the last 3 
months multiplied to represent costs across all months 
from 4 to 12. If significantly underestimated, this could be 
decisional. To date, there are no primary economic data 
beyond 12 months of an intervention and very few trials 
include measures of quality of life alongside PA. There-
fore, with respect to the long-term modelling, a key gap 
in knowledge is the likelihood of maintaining PA beyond 
12 months. This model assumes differences in PA at 1 year 
in the trial relate to the same long-term benefit associated 
with the same difference in cohort studies, but this could 
be updated once longer term follow-up data become 
available. Other challenges set out in Anokye et al’s13 
study are relevant here, for example, cancer and adverse 
events are not accounted for, which could lead to overes-
timation or underestimation of cost-effectiveness. Other 
challenges relate to the generalisability of effectiveness 
data, given the focus on South London and 10% recruit-
ment rate, even though recruitment was comparable with 
other PA trials.36 37 The trial was shown to recruit fewer: 
men, people aged 55–64 years compared with those 
over 65 years, people from the most deprived quintile 
compared with least deprived and Asian compared with 
white people.37 However, there was good representation 
of women, older adults and people who were overweight, 
all of whom are groups likely to benefit from the inter-
vention.4 Investigation into the reasons for non-participa-
tion showed an important minority cited existing medical 
conditions, too many other commitments or considered 
themselves sufficiently active.35 38
This study feeds into an area with very limited 
primary data39 40 populated only by small studies.5 6 In 
New Zealand, pedometers were shown to have a 95% 
probability of being a cost-effective addition to green 
prescriptions at 12 months,5 much higher than the 50% 
likelihood we found. Other models of long-term cost-ef-
fectiveness studies identified cost savings and improved 
quality of life at a population level from pedometers 
in the long term8 41 or indicated high probabilities of 
long-term cost.7 42 Guidance has also suggested that 
long-term monitoring/support at £25/year would be 
very cost-effective. Our study provides further support 
that pedometer-based programmes are a cost-effective 
method of improving health-related quality of life in 
both the short term and long term. Assumptions about 
intervention effectiveness beyond 1 year have mixed 
impacts, and further research is required to better judge 
whether existing models overpredict or underpredict 
cost-effectiveness.
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Current public health guidance from NICE on pedom-
eters43 advises using pedometers as ‘part of a package’ 
which includes support to set realistic goals in one-to-one 
meetings (where the number of steps taken is gradually 
increased), monitoring and feedback. Our results provide 
substantially better economic data for use by NICE and 
suggest guidance should be updated to reflect the value 
of providing pedometers to people who have made some 
form of commitment (ie, to a trial) through the post. For 
those practices that have implemented consultation-based 
distribution of pedometers, moving to postal delivery 
could save costs within a year, with similar outcomes.
Postal delivery of pedometer interventions to inactive 
people aged 45–75 through primary care is cost-effective 
in the long term and has a 50% chance of being cost-ef-
fective, through resource savings, within 1 year. Further 
research is needed to ascertain the extent to which higher 
PA levels are maintained beyond 3 years and the impact 
of PA on quality of life and general health service use in 
both the short term and long term.
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